These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1066 related articles for article (PubMed ID: 28410237)

  • 1. Combination therapy in combating cancer.
    Bayat Mokhtari R; Homayouni TS; Baluch N; Morgatskaya E; Kumar S; Das B; Yeger H
    Oncotarget; 2017 Jun; 8(23):38022-38043. PubMed ID: 28410237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.
    Bayat Mokhtari R; Baluch N; Ka Hon Tsui M; Kumar S; S Homayouni T; Aitken K; Das B; Baruchel S; Yeger H
    BMC Cancer; 2017 Feb; 17(1):156. PubMed ID: 28235409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016).
    Lomelino C; McKenna R
    Expert Opin Ther Pat; 2016 Aug; 26(8):947-56. PubMed ID: 27387065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective carbonic anhydrase IX inhibitors based on coumarin scaffold as promising antimetastatic agents: WO2012070024.
    Carradori S
    Expert Opin Ther Pat; 2013; 23(6):751-6. PubMed ID: 23387899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbonic anhydrase IX inhibitors in cancer therapy: an update.
    Supuran CT; Winum JY
    Future Med Chem; 2015; 7(11):1407-14. PubMed ID: 26230880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target.
    Drenckhan A; Freytag M; Supuran CT; Sauter G; Izbicki JR; Gros SJ
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1024-1033. PubMed ID: 29865880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tumor-associated carbonic anhydrase IX in cancer therapy.
    Thiry A; Dogné JM; Masereel B; Supuran CT
    Trends Pharmacol Sci; 2006 Nov; 27(11):566-73. PubMed ID: 16996620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
    Lock FE; McDonald PC; Lou Y; Serrano I; Chafe SC; Ostlund C; Aparicio S; Winum JY; Supuran CT; Dedhar S
    Oncogene; 2013 Oct; 32(44):5210-9. PubMed ID: 23208505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
    van Kuijk SJA; Parvathaneni NK; Niemans R; van Gisbergen MW; Carta F; Vullo D; Pastorekova S; Yaromina A; Supuran CT; Dubois LJ; Winum JY; Lambin P
    Eur J Med Chem; 2017 Feb; 127():691-702. PubMed ID: 27823879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma.
    Ameis HM; Drenckhan A; Freytag M; Izbicki JR; Supuran CT; Reinshagen K; Holland-Cunz S; Gros SJ
    J Enzyme Inhib Med Chem; 2016; 31(3):404-9. PubMed ID: 25884234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel sulfonamide compounds for inhibition of metastatic tumor growth (WO2012021963).
    Colinas PA
    Expert Opin Ther Pat; 2013; 23(6):761-3. PubMed ID: 23566197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
    Ali SR; Humphreys KJ; McKinnon RA; Michael MZ
    Drug Dev Res; 2015 Sep; 76(6):296-317. PubMed ID: 26303212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007 - 2009.
    Poulsen SA
    Expert Opin Ther Pat; 2010 Jun; 20(6):795-806. PubMed ID: 20476848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.
    Ward C; Meehan J; Mullen P; Supuran C; Dixon JM; Thomas JS; Winum JY; Lambin P; Dubois L; Pavathaneni NK; Jarman EJ; Renshaw L; Um IH; Kay C; Harrison DJ; Kunkler IH; Langdon SP
    Oncotarget; 2015 Sep; 6(28):24856-70. PubMed ID: 26259239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting carbonic anhydrase IX with small organic ligands.
    Wichert M; Krall N
    Curr Opin Chem Biol; 2015 Jun; 26():48-54. PubMed ID: 25721398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.
    Supuran CT
    Expert Opin Drug Metab Toxicol; 2016; 12(4):423-31. PubMed ID: 26878088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs.
    Dubois L; Peeters SG; van Kuijk SJ; Yaromina A; Lieuwes NG; Saraya R; Biemans R; Rami M; Parvathaneni NK; Vullo D; Vooijs M; Supuran CT; Winum JY; Lambin P
    Radiother Oncol; 2013 Sep; 108(3):523-8. PubMed ID: 23849171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.